RT Journal Article
T1 Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification
A1 Ripoll, Consuelo
A1 Roldan, Mar
A1 Ruedas-Rama, Maria J.
A1 Orte, Angel
A1 Martin, Miguel
K1 metabolic profiling
K1 breast cancer
K1 tumor metabolism
K1 metabolic reprogramming
K1 Glutamine-metabolism
K1 Aerobic glycolysis
K1 Pyruvate-kinase
K1 Growth
K1 Acid
K1 Proliferation
K1 Requirements
K1 Inhibition
K1 Synthetase
K1 Hallmarks
AB Simple Summary Recent studies on cancer cell metabolism have achieved notable breakthroughs that have led to a new scientific paradigm. How cancer cell metabolic reprogramming is orchestrated and the decisive role of this reprogramming in the oncogenic process and tumor adaptative evolution has been characterized at the molecular level. Despite this knowledge, it is essential to understand how cancer cells can metabolically respond as a living whole to ensure their survival and adaptation potential. In this work, we investigated whether different cancers and different subtypes display different metabolic phenotypes with a focus on breast cancer cell models representative of each clinical subtype. The potential results might have significant translational implications for diagnostic, prognostic and therapeutic applications. Metabolic reprogramming of cancer cells represents an orchestrated network of evolving molecular and functional adaptations during oncogenic progression. In particular, how metabolic reprogramming is orchestrated in breast cancer and its decisive role in the oncogenic process and tumor evolving adaptations are well consolidated at the molecular level. Nevertheless, potential correlations between functional metabolic features and breast cancer clinical classification still represent issues that have not been fully studied to date. Accordingly, we aimed to investigate whether breast cancer cell models representative of each clinical subtype might display different metabolic phenotypes that correlate with current clinical classifications. In the present work, functional metabolic profiling was performed for breast cancer cell models representative of each clinical subtype based on the combination of enzyme inhibitors for key metabolic pathways, and isotope-labeled tracing dynamic analysis. The results indicated the main metabolic phenotypes, so-called 'metabophenotypes', in terms of their dependency on glycolytic metabolism or their reliance on mitochondrial oxidative metabolism. The results showed that breast cancer cell subtypes display different metabophenotypes. Importantly, these metabophenotypes are clearly correlated with the current clinical classifications.
PB Mdpi
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/28400
UL https://hdl.handle.net/10668/28400
LA en
DS RISalud
RD Apr 6, 2025